DAX6.693-1,4%  Dow12.801-0,7%  Euro1,3200-0,7% 
ESt502.481-1,7%  Nas2.904-0,8%  Öl117,6-0,9% 
TDax769,9-0,4%  Nikkei8.947-0,6%  Gold1.721-0,5% 
Home > Aktien > ISIS Pharmaceuticals Aktie > Nachrichten zu ISIS Pharmaceuticals

ISIS Pharmaceuticals Aktie [WKN: 881866 / ISIN: US4643301090]

Kurse + Charts + RealtimeNews + AnalysenFundamentalUnternehmenzugeh. WertpapiereAktion
Kurs + ChartChart (groß)News + AdhocBilanz/GuVTermineZertifikateDepot
Times + SalesChart-AnalyseAnalysenDividende/HVProfilOptionsscheineWatchlist
BörsenplätzeChartvergleichKursziele InsidertradesKnock-outsmyfinanzen
OrderbuchRealtime StuttgartRSS FeedAnalyseim ForumFondsSenden
HistorischRealtime Push  IR-DatenAnleihen
handeln

Hinweis

Auf dieser Seite finden Sie ALLE Nachrichten zur ISIS Pharmaceuticals Inc.. Links ausgesuchte Top-Nachrichten, rechts weitere Meldungen.

Newssuche

 GO 

ALLE Nachrichten zur ISIS Pharmaceuticals Inc.

22.06.10Sanofi-Aventis schließt Allianz mit Regulus Therapeutics
29.03.10Regulus Therapeutics and Collaborators Publish Pre-clinical In Vivo Efficacy Data on microRNA Therapeutics targeting microRNA-10b in Models of Breast Cancer Metastasis
17.03.10Regulus Announces U.S. Allowance of Stanford Patent Application Covering miR-181a Function in Immune Cells
25.01.10Regulus, Alnylam and Isis Announce U.S. Allowance of Tuschl III Patent Application Covering miR-21
15.01.10Regulus Therapeutics Present New Pre-clinical Data from Multiple Therapeutic Programs at Keystone Symposium
11.01.10Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development
17.12.09Regulus Therapeutics Receives Exclusive License for Intellectual Property on Immuno-inflammatory microRNAs from the California Institute of Technology
09.12.09Regulus Therapeutics Inc. presents: "MicroRNA: The Year in Review and a Look Ahead”
28.10.09Regulus Announces U.S. Allowance of Fundamental microRNA Therapeutics Patent Application
17.09.09Regulus, Alnylam, and Isis Announce First microRNA Patent Grant in Japan from Tuschl III Patent Series
16.09.09Regulus Therapeutics Appoints Hubert C. Chen, M.D., Vice President of Translational Medicine
11.08.09Alnylam and Regulus Receive Notice of Allowance from United States Patent and Trademark Office for New Patent Covering microRNA Therapeutics
14.05.09Regulus Therapeutics Achieves Initial Milestone in its Inflammatory Diseases Collaboration with GlaxoSmithKline
29.04.09Isis and Alnylam Form New Collaboration to Develop Single-Stranded RNAi Technology
04.03.09Regulus Therapeutics Receives $20 Million in a Series A Equity Financing
04.03.09Regulus Therapeutics Receives $20 Million in a Series A Equity Financing
17.12.08Abbott Laboratories gibt Übernahme bekannt
30.11.08Regulus Therapeutics, Alnylam Pharmaceuticals, and Collaborators Publish First Ever In Vivo Efficacy Data for a microRNA Therapeutic in a Disease Model
06.11.08Regulus Therapeutics and Collaborators Discover Role of a microRNA in Tumor Angiogenesis
03.09.08Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors
19.08.08Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain Tumors
04.08.08Regulus Therapeutics Appoints Garry Menzel, Ph.D., as Executive Vice President Corporate Development and Finance
24.06.08Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies
06.05.08Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University Relating to microRNA Antagonists to Treat Inflammatory Diseases
11.02.08Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
12.12.07Regulus Therapeutics and Collaborators Discover Role of Viral microRNAs in Cancer and Identify First-Ever Example of a Viral microRNA Oncogene
03.12.07Regulus Therapeutics Appoints Kleanthis G. Xanthopoulos, Ph.D. as President and Chief Executive Officer
19.11.07Regulus Therapeutics Announces Allowance of Key Patent on microRNA Therapeutics for the Treatment of Hepatitis C Virus Infection
25.10.07Regulus Therapeutics and Collaborators Announce Publication of New Research on the Role of microRNAs in Regulating Pathways of Viral Infection
07.09.07Isis and Alnylam Launch Regulus Therapeutics, a Joint Venture to Discover, Develop, and Commercialize microRNA Therapeutics
07.08.07Archemix and Isis Pharmaceuticals Form Strategic Alliance for Aptamer Drug Discovery and Development
27.06.07Alnylam Announces Achievement of Key Milestone in Collaboration Agreement

Anzeige

ANZEIGE

 
Wie bewerten Sie diese Seite?
schlecht sehr gut
Aktien Prime Standard: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z DAX MDAX Dow Jones EuroStoxx

Kontakt - Impressum - Werben - Presse

finanzen.net als Startseite - Sitemap - Arbeiten bei finanzen.net - RSS-Feeds - Datenschutz - Disclaimer - Nutzungsbedingungen


Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Telekurs. Verzögerung Deutsche Börse: 15 Min., Nasdaq, NYSE: 20 Min. © 1999-2012 finanzen.net GmbH

News Aktien Kurslisten Analysen Devisen Dollarkurs Fonds Zertifikate Optionsscheine Anleihen Rohstoffe Aktien kaufen Portfolio Links Aktien China Währungsrechner Gold kaufen CFD Aktienkurse Ölpreis Leitzins Heizölpreis IPO Börsenkurse Lexikon